Sun Pharma subsidiaries settle US antitrust litigation for $200 million
Under the terms of the agreement, SPII and Taro will make a combined payment of $200 million. In return, all claims brought against them—along with their current and former parents, affiliates, predecessors, successors, directors, officers, employees, and representatives—will be fully released by the settlement class members in the End Purchaser Action.
The settlement amount may be reduced if more than a certain percentage of total insured class members opt out of the class.
Sun Pharma clarified that the settlement is being entered into without any admission of wrongdoing. The agreement remains subject to court approval.
In the meantime, Sun Pharma shares closed at ₹1,692.00 today, after opening at ₹1,682.50. During the session, the stock touched an intraday high of ₹1,696.00 and a low of ₹1,680.10. The stock remains below its 52-week high of ₹1,960.35, while staying comfortably above the 52-week low of ₹1,553.05.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Trump to add 25% tariff to Indian imports. Which everyday goods could be impacted?
President Donald Trump announced the United States will impose a 25% tariff on Indian goods starting Aug. 1, after months of negotiations over a limited trade agreement between the two nations appeared to fall through. Trump announced the new tariff in a post on his social media app Truth Social on July 30, two days before a bevy of increased reciprocal tariffs will go into effect for dozens of nations on Aug. 1. These new import levies come amid an existing baseline tariff of 10%, and Trump warned this week that most trading partners that do not negotiate separate trade deals could soon face new baseline tariffs of 15% to 20%. India, the world's fifth-largest economy, relies significantly on the U.S., counting it as its top trading partner in 2024, though China is close on its heels by a small margin. Learn more: President Trump announces 25% tariff on imports from India Indian goods exports to the U.S. totaled $87 billion in 2024, with pharmaceuticals and jewelry among its top product types, followed by petrochemicals and textiles. Separately, services exports, mainly IT and professional services, were worth $33 billion last year. The U.S. is India's third-largest investor, and currently has a $45.7 billion trade deficit with the South Asian nation. Here are some of the products the U.S. relies on most from India, according to data from the U.S. International Trade Commission: Pharmaceuticals The U.S. accounts for nearly a third of India's pharmaceutical exports, mainly cheaper versions of popular drugs, Reuters reports, with sales jumping 16% to about $9 billion last fiscal year. Among the dozens of types of medications the U.S. imports from India, a few classifications make up a significant share. They are items like wadding, gauze and bandages; antineoplastic and immunosuppressive medications, including those used to treat cancers; and analgesics, antipyretics and nonhormonal anti-inflammatory agents, such as pain relievers and medications used to reduce fevers. Smartphones Though China and Vietnam were responsible for more than half of phones sent to the U.S. last year, India also produces a significant share, and looks to be gaining a firmer foothold in the market. According to a new report, India has overtaken China in the last few months as the top exporter of smartphones to the U.S., following Apple's pivot to center manufacturing in New Delhi amid tariff concerns. The share of U.S. smartphone shipments assembled in China fell from 61% to 25% over the past year, the research firm Canalys said, with India picking up most of the decline and increasing its smartphone volume by 240% roughly within the same time frame. More: Trump's trade talks intensify with tariff deadline fast approaching Jewelry and precious stones Next to pharmaceuticals, jewelry and precious stones are among India's top products exported to American consumers. More than 30% of India's gems and jewelry exports go to the U.S., accounting for about $10 billion in annual trade in an industry that topped $30 billion in India in the 2023/2024 fiscal year. These goods include unmounted or unset diamonds, precious metal jewelry and jewelry clad with precious metal − such as pieces plated with gold or silver. Home linens India is among the top countries responsible for imported home linens in the U.S., representing 36% of nearly $6 billion in imports, according to a New York Times analysis of government data. These products include bathroom and kitchen linen made of terrycloth or cotton, along with bed and table linens. India is also a leader in some types of imported clothing, such as activewear, shirts, baby clothes and suits. According to the Yale Budget Lab, the tariff hikes so far have disproportionately affected clothing and textiles, with consumers facing up to 39% higher shoe prices and 37% higher apparel prices in the short run. Other products The U.S. also relies on Indian imports of frozen shrimp and prawns, petroleum oils such as transformer oil and motor fuel, semiconductor technologies like solar panels and certain types of electrical machinery and parts. Contributing: Reuters. Kathryn Palmer is a national trending news reporter for USA TODAY. You can reach her at kapalmer@ and on X @KathrynPlmr. This article originally appeared on USA TODAY: Trump imposes tariff on India: What products will be affected? Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Novo Nordisk (NVO) Sell-Off Wipes Billions in Market Value
July 30- Novo Nordisk (NYSE:NVO) continued to slide 7% on Wednesday after the Danish drugmaker cut its full?year outlook. Slower growth in its obesity franchise, led by semaglutide, weighed down the company's performance. Warning! GuruFocus has detected 1 Warning Sign with NVO. The company now sees sales rising 8%14% and operating profit up 10%16% on a currency?adjusted basis, down from prior forecasts of 13%21% and 16%24%. Management cited weaker U.S. demand for Wegovy and Ozempic amid rising competition from compounded GLP?1 therapies. Investors dumped shares fast. The sell-off erased an estimated $70 billion in market value, slashing Novo Nordisk's valuation to around $287 billion, down from roughly $357 billion a day earlier. Technical indicators show heightened selling pressure, with the 14?day Relative Strength Index at 26.4below the 30?level that often signals an oversold stock. NVO remains 64.9% below its record intraday high of $148.15 reached in June 2024. Some analysts maintain a positive stance despite the outlook cut. They point to Novo Nordisk's dominant GLP?1 pipeline and expect oral Wegovy approvals to support long?term growth, though they warn that near?term volatility may persist. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
5 hours ago
- Forbes
InnovationRx: Trump's EU Tariff Deal Will Add $13 Billion To Drug Costs
In this week's edition of InnovationRx, we look at the impact of Trump's tariffs on drugs made in Europe, Halle Berry's menopause startup, Ambience Healthcare's $243 million fundraise, and more. To get it in your inbox, subscribe here . Eli Lilly's plant in Kinsale, Ireland Bloomberg Finance F or months, there have been questions about what the impact of Trump's tariffs on drugs would be. On Sunday, we got part of the answer: Under the trade deal reached between the U.S. and the European Union, medicines imported from Europe will face a 15% tariff. That tax hike will hit some of the biggest blockbuster drugs, including Keytruda (for cancer) and Wegovy (for obesity), as well as less well-known brand name medications. Questions remain about generics: European Commission President von der Leyen said on Sunday that certain generics would be exempt, but the White House fact sheet on the deal lists no such exceptions. What is clear, though, is that the cost of the tariff will likely be passed to American consumers, both directly and indirectly through higher insurance premiums. ING analyst Diedrick Stadig told Forbes that once stockpiled medicines are gone, the tax would add around $13 billion to the cost of imported drugs. There will be indirect costs, too. As companies look to manage the impact of Trump's tariffs by building out U.S. manufacturing, they could potentially cut spending in other areas, including research and development, to compensate, Emarketer analyst Rajiv Leventhal told Forbes . 'They're going to have to cut back in other areas to not have Wall Street panic,' he said. Halle Berry Cliff Watts for Forbes In May 2024, Halle Berry, the actress and former model, shouted three words on Capitol Hill to a bipartisan group of senators (all women): ' I'm in menopause! ' Berry, now 58, first became focused on the issue, as both an entrepreneur and an advocate, after her own perimenopause was misdiagnosed as herpes. She originally founded Respin as a wellness and exercise website in 2020, but relaunched it this February as a menopause-focused healthcare company. With less than $5 million in funding from investors including Khosla Ventures, Respin is still in its earliest days. Telehealth visits just launched in July and revenue is mostly nonexistent. But Berry's work, profiled in Forbes as part of this year's 50 Over 50 list, is just one indication, along with VC-backed Midi Health, which has raised more than $100 million, that menopause is finally getting some attention. 'This is my greatest act,' Berry tells Forbes. 'And I couldn't have imagined that this would be my greatest act because I think as women, we've been afraid to age.' Read more here. BIOTECH AND PHARMA Sarepta Therapeutics is again shipping its gene therapy Elevidys for patients with Duchene muscular dystrophy (a particularly severe form of the disease) who are able to walk. The latest move came after the FDA recommended the removal of a voluntary hold it had previously placed on the drug. The face-off between Sarepta and the FDA followed the deaths of three people from Elevidys or a similar drug (that's in early-stage clinical trials) from liver failure. Duchenne patients and their families had put pressure on the FDA to reverse the decision, though the agency said it will continue to investigate the deaths. On Tuesday night, Vinay Prasad, the FDA's top vaccine and gene therapy official, abruptly resigned after just three months after he took the job. Prasad, head of the Center for Biologics Evaluation and Research, had faced heavy criticism from the right over his handling of Sarepta, including an op-ed from The Wall Street Journal 's editorial board and derision from pro-Trump influencer Laura Loomer. The Health and Human Services Department has not yet said who will fill his role. DIGITAL HEALTH AND AI Open AI-backed startup Ambience Healthcare raised $243 million – one of the year's largest VC investments in healthtech – led by Oak HC/FT and Andreessen Horowitz. The new funding increases Ambience's valuation to more than $1 billion, according to Bloomberg. Founders Michael Ng, the company's CEO, and Nikhil Buduma, its chief scientist, previously founded digital health startup Remedy Health. Plus: Sword Health, the $4 billion (valuation) digital health startup, launched a new AI division to help payers and providers increase operational efficiency. MEDTECH Imagine getting a heart valve replacement and being able to resume your normal, daily activities a week later. That's the reality for four patients at the Cleveland Clinic, according to case studies it presented earlier this year. Its surgeons were able to use robots to perform the aortic valve replacement surgery through the patients' necks, avoiding the need for open-heart surgery and its accompanying long, painful recovery. One patient even reported he'd resumed running in the gym a week after he was discharged. PUBLIC HEALTH AND HOSPITALS Millions of undergraduate and graduate students rely on Medicaid for health coverage. As long as they attend school more than half-time, they should meet the new work requirement added in the recently passed 'One Big Beautiful Bill'. But yet-to-be issued rules and procedures, along with paperwork problems and administrative snafus, could still put many of them at risk. One big problem: The law doesn't actually define what 'half-time enrollment' means. Another: The law requires applicants to look back one month to see if they met the work requirement, and it's unclear what that means for a new student who was, for example, on summer break the month before they enrolled. This and many other unanswered questions will likely leave millions of college students' health insurance in limbo as the legislation is implemented. WHAT WE'RE READING Some psychiatric patients may actually have treatable autoimmune conditions. The New Yorker explores the story of one schizophrenia patient who suddenly recovered. Scientists are using AI to boost efforts to spot flags for diseases of extreme tiredness, including long COVID and chronic fatigue syndrome. China is facing a major outbreak of the mosquito-borne disease chikungunya, which has infected more than 4,000 people. White House officials scrapped a plan by the Office of Management and Budget that would have effectively halted NIH grants, and the funds are set to flow again. Tribal health officials are working to fill in vaccination gaps as the U.S. measles outbreak continues to spread. UnitedHealth Group's profit fell to $3.4 billion in the second quarter, from $4.2 billion in the same period last year, as it grapples with rising costs of providing health insurance to millions of Americans. Shares of Novo Nordisk, which makes Wegovy and Ozempic, dropped more than 21% Tuesday, after it cut its guidance to analysts on sales and profit for the year. MORE FROM FORBES Forbes The Tech Mogul Behind Trump's Truth Social Used To Own Porn Domains By Emily Baker-White Forbes How The World's Second-Richest Person And His Son Pulled Off The $8 Billion Paramount Deal By Phoebe Liu Forbes Trump Has Spent About One-Third Of His Presidency Visiting His Own Properties By Dan Alexander
